Objectives-Radial artery access (RA) for left heart catheterization and percutaneous coronary interventions (PCIs) has been demonstrated to be safe and effective. Despite consistent data showing less bleeding complications compared with femoral artery access (FA), it continues to be underused in the United States, particularly in patients with acute coronary syndrome (ACS) in whom aggressive anticoagulation and platelet inhibition regimens are needed. This systematic review and meta-analysis aims to compare major cardiovascular outcomes and safety endpoints in patients with ACS managed with PCI using radial versus femoral access.
compared RA and FA during PCI in patients with ACS and measured at least one of the following cardiovascular outcomes: mortality, major adverse cardiac events (MACE), major bleeding, and access-related complications. We excluded studies with fewer than 100 patients because of the small sample size that may influence the results. We also excluded studies and registries that examined the outcome retrospectively. 19 
Data Abstraction
Two reviewers working in duplicate and independently used a standardized form to abstract the data from each study. Any discrepancies were resolved by consensus and arbitration by a third investigator (A.A.L.). For each outcome, absolute event numbers were extracted and results are expressed as a ratio of total participants with complete follow-up. The longest follow-up data available were used for each study.
Quality Assessment
The criterion of Jüni et al 20 was used to ascertain the methodological quality and the potential for bias of included randomized trials. A modified Newcastle-Ottawa scale 21 was used to assess the quality of registry studies (details included in the online-only supplemental material). Briefly, the authors evaluated the study quality based on the following criteria: adequacy of allocation, appropriate description of randomization method, similarity of groups at the onset of the study, blinding for both participants and caregivers, blind ascertainment of outcomes, attrition, and intention to treat analysis. The authors' statements regarding blinding and other methods in the original manuscripts were accepted verbatim.
Data Analyses
We performed a meta-analysis of the RCTs and cohort studies comparing clinical outcomes of patients with ACSs undergoing PCI using either RA or FA for their index procedure. The prespecified outcomes of our analyses were all-cause mortality, MACE, major bleeding, and access-related complications. Given the inherent difference in study design, we performed separate meta-analyses for the RCTs and the cohort studies. 22 This was followed by a pooled estimate for all of the studies. Because MACE had different definitions in the incorporated studies, we only included studies that specifically reported the outcome and used a traditional definition of its components. For mortality, some studies used all-cause mortality, whereas others used cardiac mortality. Given the observed heterogeneity in the study methods, we conducted random effects meta-analyses to obtain estimated odds ratios (ORs) for the prespecified main clinical outcomes comparing radial versus femoral access and their associated 95% confidence intervals (CIs). The estimated OR from separate studies was combined according to the DerSemonian-Laird method. 23 We calculated the number needed to treat (NNT) and the number needed to harm (NNH) to assess clinical relevance of the results. The NNT and NNH are the reciprocal of the estimated risk difference calculated based on the Mantel-Haenzel method. NNT denotes the number of patients who would need to be treated with radial access PCI instead of FA PCI to prevent one adverse event, whereas NNH denotes the number of patients who would need to be treated with FA PCI instead of RA PCI to cause one adverse outcome in this analysis. We estimated the proportion of between-study inconsistency resulting from true differences among studies (rather than differences from chance) using the I 2 statistic, 24 with values of 25%, 50%, and 75% considered low, moderate, and high, respectively. Funnel plots were graphically explored for evidence of publication bias. RevMan version 5.1.2 (Copenhagen, Denmark) was used for these analyses.
Results

Search Results
Of 295 articles retrieved during the initial search (Fig. 1 A ) , 46 were not original investigations (review articles and editorials) and 217 were not pertinent to the study question (study design was not pertinent to the meta-analysis question or the clinical outcomes were not reported adequately). Thirty-two studies (15 RCTs and 17 cohorts) containing 44,854 patients were found eligible for inclusion in the meta-analysis. Of these 44,854 patients, 10,482 (23%) underwent RA and 34,372 (77%) underwent FA PCI. Interreviewer agreement on study eligibility was 100%.
Study Characteristics
The main characteristics of the included trials for both RCTs and cohort studies are presented in Table 1 . Overall, the median number in cohort studies was larger than that in the RCTs (306 vs 63 patients per group). The age reflects the general clinical practice for patients with ACS and was equal in RCTs and cohort studies (median age 62 years in RCTs and 61.75 in cohort studies). Twelve of the 15 RCTs and 14 of the 17 cohort studies included patients with STEMI exclusively. None of the RCTs included patients with cardiogenic shock, whereas 6 of the 17 cohort studies included this patient category.
Study Quality
Several metrics were used to assess the data quality and reliability of this meta-analysis result. Supplemental Table 1 (http://links.lww.com/SMJ/A42) presents the well-balanced methodological quality of the RCTs. Because blinding to the access site is not logistically feasible, it was not achieved in any of the included studies. We judged whether the follow-up was adequate based on the expected time frame of occurrence of major bleeding and access site complications; however, 12 of the 17 studies had a follow-up duration of ≤30 days, which may not be adequate to assess the rates of mortality or MACE. Follow-up was complete in all of the included RCTs except in the study by Gan et al, 26 in which 12% to 16% of the study population was lost to follow-up. Supplemental Table 2 (http:// links.lww.com/SMJ/A43) presents the quality of the cohort studies. All 17 observational studies received favorable ratings on 6 of the 8 domains, but ratings were lower on assessment of outcome and comparability. None of the studies blinded the caregivers to access assignment. The interreviewer agreement on these quality domains was 90%.
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Meta-analyses
Overall Sample-A total of 1378 patients (3.2%) died during follow-up: RA was associated with a significant reduction in mortality (2.1% vs 3.4%, OR 0.64, 95% CI 0.54-0.75, P < 0.001); this reduction was observed in both RCTs (1.9% vs 2.7%, OR 0.69, 95% CI 0.53-0.90, P = 0.006) and cohort studies (2.3% vs 3.6%, OR 0.61, 95% CI 0.50-0.74, P < 0.001). MACE was observed in 2788 patients (6.7%) and RA was associated with a significant reduction in MACE as compared with FA (5.0% vs 7.2%, OR 0.84, 95% CI 0.76-0.94, P < 0.01). This reduction was significant only in cohort studies (6.2% vs 7.6%, OR 0.85, 95% CI 0.75-0.97, P < 0.01).
A total of 38,522 patients were analyzed for major bleeding, 10,709 of whom (28%) underwent RA procedures and 27,813 (72%) underwent FA procedures (Fig. 2) . Major bleeding was observed in 1047 patients (2.7%). Among those, RA reduced the risk of major bleeding by 55% compared with FA (1.4% vs 3.2%, OR 0.45, 95% CI 0.33-0.61, P < 0.001). This reduction was significant in both RCTs (1.0% vs 2.0%, OR 0.54, 95% CI 0.37-0.80, P = 0.002) and cohorts (1.8% vs 3.5%, OR 0.39, 95% CI 0.25-0.61, P < 0.001).
Furthermore, 31,409 patients were analyzed for access-related complications, 8952 of whom underwent RA and 22,457 of whom underwent FA (Fig. 3) . Access-related complications were observed in 909 patients (2.9%). RA was superior to FA in terms of the risk of accessrelated complications (1.2% vs 3.6%, OR 0.27, 95% CI 0.18-0.39, P < 0.001). This benefit was observed in both RCTs (1.9% vs 4.9%, OR 0.38, 95% CI 0.30-0.49, P < 0.001) and cohorts (1.2% vs 3.1%, OR 0.12, 95% CI 0.06-0.27, P < 0.001).
Analysis of the STEMI Population-We conducted a separate analysis for studies involving only patients with STEMI to evaluate potential differences in outcomes when compared with non-ST elevation ACS. A total of 12,944 patients were analyzed for mortality outcomes. Of these patients, 4329 (33%) underwent RA and 8615 (67%) underwent FA. A total of 520 patients (4%) died during follow-up. Among them, RA was associated with an overall reduction in mortality (2.8% vs 4.6%, OR 0.61, 95% CI 0.49-0.76, P < 0.001). This reduction was observed in both RCTs (3.4% vs 5.8%, OR 0.57, 95% CI 0.39-0.82; P = 0.003) and cohort studies (2.6% vs 4.4%, OR 0.63, 95% CI 0.48-0.84, P = 0.002). A total of 12,931 patients were analyzed for MACE, 5081 of whom (39%) underwent RA and 7850 (61%) underwent FA (Fig. 4) . MACE was observed in a total of 657 patients (5.8%). RA was associated with a significant reduction in MACE as compared with FA (4.3% vs 6.4%, OR 0.55, 95% CI 0.45-0.68, P < 0.001), both in RCTs (5.8% vs 8.1%, OR 0.67, 95% CI 0.49-0.90, P < 0.01) and cohorts (3.3% vs 6.1%, OR 0.45, 95% CI 0.34-0.60, P < 0.001). A total of 14,026 patients were analyzed for major bleeding, 4868 (34.7%) of whom underwent RA and 9158 (65.3%) of whom underwent FA. Major bleeding was observed in 432 patients (3.0%). Among those, RA reduced the risk of major bleeding significantly compared with FA (1.7% vs 3.8%, OR 0.38, 95% CI 0.26-0.57, P < 0.001), both in RCTs (1.9 % vs 4.7%, OR 0.45, 95% CI 0.29-0.70 P = 0.0004) and cohorts (1.6% vs 3.6%, OR 0.31, 95% CI 0.16-0.59, P = 0.0004). Furthermore, 6913 patients were analyzed for access-related complications; 3111 (45%) underwent RA and 3802 (55%) underwent FA. Access-related complications were observed in 320 patients (4.6%). RA was significantly superior to FA in reducing the risk of access-related complications (1.5% vs 7.2%, OR 0.25, 95% CI 0.15-0.39, P < 0.001), both in RCTs (2.6% vs 7.1%, OR 0.36, 95% CI 0.24-0.54, P < 0.001) and cohorts (0.5% vs 7.2%, OR 0.09, 95% CI 0.03-0.29, P < 0.001).
Sensitivity Analyses-We also conducted sensitivity analyses comparing randomized with cohort studies to explore the possibility of selection bias in our results. There were no significant differences between the outcomes in both arms and we did not observe any significant interactions (Table 2) . Similarly, we did not observe significant interactions among studies that enrolled patients with STEMI compared with studies that included patients with ACS (Table 3 ). Our findings were unchanged when we again performed the meta-analysis using the fixed-effects instead of the random-effects model (data not shown). The heterogeneity observed in our analyses was generally in the low-to-moderate range, and we elected to present the data from the random-effects model.
The absolute risk difference in major bleeding was 2% (CI 3%-1%, P < 0.001) with NNT of 50 individuals. The absolute risk difference in access site complications was 4% (CI 6%-3%, P = 0.001) with NNT of 25 individuals. The absolute risk difference in MACE was 2% (CI 3%-1%, P = 0.01) with NNT of 50 individuals. The absolute risk difference in mortality was 1% (CI 2%-1%, P < 0.001) with NNT of 100 individuals. This reduction in absolute risk difference and subsequent NNT was consistent among RCTs and cohort studies.
Heterogeneity Analysis-Tests for heterogeneity were performed for each of the clinical endpoints using the I 2 statistic. We also examined funnel plots to assess publication bias (supplemental Fig. 1 , http://links.lww.com/SMJ/A44 [Funnel plots of the included studies showing the lack of publication bias and the consistency of the study results around the overall odds ratio estimate. The plots were constructed for each outcome separately.]). Overall, the heterogeneity in our analyses based on the I 2 statistic was moderate (approximately 40%) except for mortality, for which the heterogeneity was low (0%). We drew funnel plots to seek evidence of publication bias; where inconsistency was high, the funnel plots were not interpretable and where inconsistency was low, the funnel plots were inconclusive.
Discussion
This comprehensive meta-analysis including RCTs and cohort studies demonstrates that RA access for PCI in the setting of ACS is safer and associated with better cardiovascular outcomes compared with FA (Figs. 5-9 ). We demonstrated a significant reduction in mortality, MACE, major bleeding, and access-related complications with RA. This benefit was consistent across multiple study designs, clinical scenarios, and patient populations. This is the largest and most comprehensive meta-analysis to date to address this important clinical scenario, and the results presented herein support the adoption of RA for PCI even in the setting of emergency primary PCI.
We included data from 32 studies and found significant reduction in mortality from RA when PCI was performed in ACS in both RCTs and cohort studies. The mechanism by which RA reduces mortality and MACE in patients with ACS may be directly related to the prevention of both major bleeding and access-related complications. Although the responsible mechanism of increased mortality in populations with major bleeding is uncertain, bleeding complications have been strongly linked to mortality in patients undergoing coronary angiography and PCI. [10] [11] [12] [13] Data from the Acute Catheterization and Urgent Intervention Triage strategY trial demonstrated that the increased risk of mortality associated with significant bleeding events is comparable to those experiencing a recurrent myocardial infarction. 11 FA has been associated with higher rates of bleeding and vascular access complications as compared with RA. The cardinal finding of our analyses is the significant reduction in vascular access complications as well as bleeding. These reductions were consistent both in RCTs and cohort studies. In addition, when we limited the analyses to patients with STEMI who traditionally have higher incidences of bleeding and vascular complications, these reductions in bleeding and access site complications remained significant. Our findings are consistent with results from a study based on the National Cardiovascular Data (CathPCI) registry examining 2,820,874 procedures ranging from elective (40%) to urgent (40%) to emergent (20%) and salvage (0.4%) PCI. 14 The results demonstrated the superiority of RA, which was associated with lower adjusted risk of bleeding (OR 0.51, 95% CI 0.49-0.54) and vascular access complications (OR 0.39, 95% CI 0.31-0.50). These reductions were consistent among different age groups, sexes, and clinical presentations. Of note, the registry population included significant percentage of patients with STEMI (18%) and patients with non-ST elevation ACS (62%). 14 Although the cumulative data showed a reduction in MACE with adopting RA, some of the studies included did not show consistent benefit in terms of MACE. When we restricted the analysis to patients with STEMI, we observed greater reduction in MACE when adopting RA. We believe that patients with STEMI benefit more because of the greater reduction in bleeding, particularly with the higher dose of antithrombotic/antiplatelet therapy used in this group. Overall, the benefit was observed more in cohort studies compared with RCTs and this can be explained by selection bias in these studies. It is important to point out that RA is associated with a learning curve, and it is essential that before adopting an RA ACS/STEMI program, operators and institutions must develop their skills in less challenging, low-acuity patient populations. There is evidence that operator and institutional expertise play a major role in the relation between RA and prevention of MACE. This suggests that adopting a high-volume radial program will bring additional benefits to a wide range of patients. 35 Many of the studies contained in our meta-analysis were intention to treat and were associated with significant crossover rates between RA and FA (5.6% and 1.2%, respectively). The RadIal Vs femorAL access for coronary intervention study, one of the largest RCTs in our analysis, had a crossover rate of 7.3%, and when significant accessrelated bleeding events were analyzed, the location of these bleeding events was found to be in the FA site, mainly in the crossover group when RA access was not possible. Of note, this study was excluded from our STEMI-focused analysis because it included patients with STEMI and non-STEMI diagnoses. We repeated the analyses excluding studies that had significant crossover, and the significant benefits of RA persisted (data not shown). Overall, the rates of crossover also were higher in the RA-assigned group.
Our meta-analysis has a number of potential limitations. We relied on published data because we did not have access to patient-level data that could have allowed for more accurate and detailed analysis of subgroups. We also included both RCTs and cohort studies; however, we analyzed each subset separately and our sensitivity analysis did not find any significant interactions between the results of RCTs and cohort studies except for access site complications, which were significantly lower in cohort studies. This can be explained by possible selection bias in cohort studies-operators may have selected RA in patients with a higher risk of access site complications, for instance. Finally, although the analyzed studies included mostly patients with STEMI, we opted to use the term ACS with or without STelevation, because this broadly represented the overall population. We conducted a sensitivity analysis among studies that exclusively enrolled patients with STEMI compared with those that included all patients with ACS, and there was no significant interaction between the two groups.
Conclusions
This meta-analysis of randomized and cohort studies showed that among patients with ACS with or without ST-elevation undergoing primary PCI, RA is associated with consistent reductions in mortality, MACE, major bleeding, and access site-related complications. As such, RA should be considered the default approach in patients with ACS, as recommended in expert consensus documents.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. 
Key Points
• Radial artery access (RA) for coronary angiography and interventions offers equivalent success rates to femoral artery access in patients with acute coronary syndromes.
• RA access for coronary angiography and interventions is associated with significantly lower access-related complication and bleeding rates compared with femoral artery access in patients with acute coronary syndromes.
• The benefits of RA access for coronary angiography and interventions extend across different study designs, patient populations, and clinical scenarios. As such, these data should encourage the wide adoption of RA in clinical practice. Forest plot of unadjusted odds ratios (ORs; 95% confidence intervals [CIs]) for major bleeding after percutaneous coronary intervention in patients with acute coronary syndromes undergoing radial artery access (RA) compared with femoral artery access (FA). A total of 38,522 patients were analyzed for major bleeding, 10,709 of whom (28%) underwent RA and 28,976 (75%) underwent FA. Major bleeding was observed in a total of 1047 patients (2.7%). RA was associated with a reduction in major bleeding as compared with FA (1.4% vs 3.2%, OR 0.45, 95% CI 0.33-0.61; P < 0.001), similarly in both randomized controlled trials (1.0% vs 2.2%, OR 0.54, 95% CI 0.37-0.80, P = 0.002) and cohorts (1.8% vs 3.5%, OR 0.39, 95% CI 0.25-0.61, P < 0.001).
Fig. 3.
Forest plot of unadjusted odds ratios (ORs; 95% confidence intervals [CIs]) for accessrelated complications after percutaneous coronary intervention in patients with acute coronary syndromes undergoing radial artery access (RA) compared with femoral artery access (FA). A total of 31,409 patients were analyzed for access-related complications, 8952 of whom underwent RA and 22,457 underwent FA. Access-related complications were observed in 909 patients (2.9%). RA was associated with a reduction in access-related complications compared with FA (1.2% vs 3.6%, OR 0.27, 95% CI 0.18-0.39, P < 0.001), Forest plot of unadjusted odds ratios (ORs; 95% confidence intervals [CIs]) for major adverse cardiovascular events (MACE) after percutaneous coronary intervention in patients with acute coronary syndromes undergoing radial artery access (RA) compared with femoral artery access (FA). A total of 38,520 patients were analyzed for MACE, 9544 (25%) of whom underwent RA and 28,976 (75%) underwent FA. MACE was observed in a total of 2608 patients (6.8%). RA was associated with a reduction in MACE as compared with FA (5.0% vs 7.3%, OR 0.70, 95% CI 0.57-0.85, P < 0.001). This significant reduction was only observed in cohort studies (6.4% vs 7.9%, OR 0.61, 95% CI 0.44-0.84, P < 0.01), however. Forest plot of unadjusted odds ratios (ORs; 95% confidence intervals [CIs]) for mortality after percutaneous coronary intervention in patients with acute coronary syndromes undergoing radial artery access (RA) compared with femoral artery access (FA). A total of 43,714 patients were analyzed for mortality, 10,696 (25%) of whom underwent RA and 33,018 (75%) underwent FA. A total of 1378 patients (3.2%) died during follow-up. RA was associated with an overall reduction in mortality (2.1% vs 3.4%, OR 0.64, 95% CI 0.54-0.75, P < 0.001). Benefits were observed in both randomized controlled trials (1.9% vs 2.7%, OR 0.69, 95% CI 0.53-0.90, P = 0.006) and cohort studies (2.3% vs 3.6%, OR 0.61, 95% CI 0.50-0.74, P < 0.001). Forest plot of unadjusted odds ratios (ORs; 95% confidence intervals [CIs]) for major bleeding after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction undergoing radial artery access (RA) compared with femoral artery access (FA). A total of 107,208 patients were analyzed for major bleeding, 4868 of whom (34.7%) underwent RA and 9158 (65.3%) underwent FA. Major bleeding was observed in a total of 432 patients (3.0%). RA was associated with a reduction in major bleeding as compared with FA (1.7% vs 3.8%, OR 0.38, 95% CI 0.26-0.57, P < 0.001), similarly in both Forest plot of unadjusted odds ratios (ORs; 95% confidence intervals [CIs]) for accessrelated complications after primary percutaneous coronary intervention in patients with STelevation myocardial infarction undergoing radial artery access (RA) compared with femoral artery access (FA). A total of 6913 patients were analyzed for access-related complications, 3111 (45%) of whom underwent RA, and 3802 (55%) of whom underwent FA. Accessrelated complications were observed in 320 patients (4.6%). RA was associated with a reduction in access-related complications compared with FA (1.5% vs 7.2%, OR 0.25, 95% CI 0.15-0.39, P < 0.001), similarly in both randomized controlled trials (2.6% vs 7.1%, OR Forest plot of unadjusted odds ratios (ORs; 95% confidence intervals [CIs]) for major adverse cardiovascular events (MACE) after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction undergoing radial artery access (RA) compared with femoral artery access (FA). A total of 12,931 patients were analyzed for MACE, 5081 (39%) of whom underwent RA and 7850 (61%) of whom underwent FA. MACE was observed in a total of 751 patients (5.8%). RA was associated with a reduction in MACE as compared with FA (4.5% vs 7.1%, OR 0.55, 95% CI 0.45-0.68, P < 0.001), similarly in both randomized controlled trials (3.4% vs 6.6%, OR 0.67, 95% CI 0.5-0.90, P = 0.009) and cohorts (3.5% vs 6.6%, OR 0.46, 95% CI 0.34-0.63, P < 0.001). Forest plot of unadjusted odds ratios (ORs; 95% confidence intervals [CIs]) for mortality after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction undergoing radial artery access (RA) compared with femoral artery access (FA). A total of 12,944 patients were analyzed for mortality outcomes, 4329 (33%) of whom underwent RA and 8615 (67%) of whom underwent FA. A total of 520 patients (4%) died during follow-up. In the meta-analysis, RA was associated with an overall reduction in mortality (2.8% vs 4.6%, OR 0.61, 95% CI 0.49-0.76, P < 0.001). Benefits were observed in both randomized controlled trials (3.4% vs 5.8%, OR 0.57, 95% CI 0.39-0.82, P < 0.003) and cohort studies (2.6% vs 4.4%, OR 0.63, 95% CI 0.48-0.84, P = 0.002).
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Ruiz-Rodriguez et al. Page 30 Table 2 Estimated ORs and 95% CIs of MACEs in RA vs FA in RCTs vs cohort studies ACS, acute coronary syndrome; CI, confidence interval; FA, femoral artery access; MACE, major adverse cardiac event; OR, odds ratio; RA, radial artery access; STEMI, ST-elevation myocardial infarction.
